KAZIA THERAPEUTICS-SPON ADR (KZIA) Fundamental Analysis & Valuation

NASDAQ:KZIA • US48669G3039

Current stock price

13.64 USD
+1.22 (+9.82%)
Last:

This KZIA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. KZIA Profitability Analysis

1.1 Basic Checks

  • In the past year KZIA has reported negative net income.
  • KZIA had negative earnings in each of the past 5 years.
  • In the past 5 years KZIA always reported negative operating cash flow.
KZIA Yearly Net Income VS EBIT VS OCF VS FCFKZIA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • KZIA has a better Return On Assets (-32.06%) than 61.16% of its industry peers.
  • Looking at the Return On Equity, with a value of -49.07%, KZIA is in the better half of the industry, outperforming 62.14% of the companies in the same industry.
Industry RankSector Rank
ROA -32.06%
ROE -49.07%
ROIC N/A
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KZIA Yearly ROA, ROE, ROICKZIA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600

1.3 Margins

  • KZIA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZIA Yearly Profit, Operating, Gross MarginsKZIA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K -800K -1M

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. KZIA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, KZIA has more shares outstanding
  • KZIA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, KZIA has a worse debt to assets ratio.
KZIA Yearly Shares OutstandingKZIA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M
KZIA Yearly Total Debt VS Total AssetsKZIA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • An Altman-Z score of 1.95 indicates that KZIA is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • KZIA's Altman-Z score of 1.95 is fine compared to the rest of the industry. KZIA outperforms 65.05% of its industry peers.
  • KZIA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • KZIA has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.95
ROIC/WACCN/A
WACCN/A
KZIA Yearly LT Debt VS Equity VS FCFKZIA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • KZIA has a Current Ratio of 2.87. This indicates that KZIA is financially healthy and has no problem in meeting its short term obligations.
  • KZIA has a worse Current ratio (2.87) than 64.27% of its industry peers.
  • A Quick Ratio of 2.87 indicates that KZIA has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.87, KZIA is not doing good in the industry: 62.33% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.87
KZIA Yearly Current Assets VS Current LiabilitesKZIA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. KZIA Growth Analysis

3.1 Past

  • KZIA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.60%, which is quite impressive.
  • Looking at the last year, KZIA shows a very negative growth in Revenue. The Revenue has decreased by -89.49% in the last year.
  • KZIA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.58% yearly.
EPS 1Y (TTM)94.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.46%
Revenue 1Y (TTM)-89.49%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, KZIA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.98% on average per year.
  • KZIA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 341.15% yearly.
EPS Next Y79.58%
EPS Next 2Y35.4%
EPS Next 3Y22.59%
EPS Next 5Y14.98%
Revenue Next Year179.1%
Revenue Next 2Y32.15%
Revenue Next 3Y125.77%
Revenue Next 5Y341.15%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KZIA Yearly Revenue VS EstimatesKZIA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
KZIA Yearly EPS VS EstimatesKZIA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

1

4. KZIA Valuation Analysis

4.1 Price/Earnings Ratio

  • KZIA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year KZIA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZIA Price Earnings VS Forward Price EarningsKZIA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZIA Per share dataKZIA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • KZIA's earnings are expected to grow with 22.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.4%
EPS Next 3Y22.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KZIA Dividend Analysis

5.1 Amount

  • KZIA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KZIA Fundamentals: All Metrics, Ratios and Statistics

KAZIA THERAPEUTICS-SPON ADR

NASDAQ:KZIA (4/30/2026, 8:00:03 PM)

13.64

+1.22 (+9.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)03-19
Earnings (Next)N/A
Inst Owners34.26%
Inst Owner Change0.15%
Ins Owners14.91%
Ins Owner Change0%
Market Cap155.86M
Revenue(TTM)246.20K
Net Income(TTM)-22.80M
Analysts82.5
Price Target19.38 (42.08%)
Short Float %956.34%
Short Ratio0.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)274%
Revenue NY rev (3m)274%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 883.9
P/FCF N/A
P/OCF N/A
P/B 4.68
P/tB 4.8
EV/EBITDA N/A
EPS(TTM)-1.78
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.02
BVpS2.91
TBVpS2.84
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -32.06%
ROE -49.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.87
Altman-Z 1.95
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.46%
EPS Next Y79.58%
EPS Next 2Y35.4%
EPS Next 3Y22.59%
EPS Next 5Y14.98%
Revenue 1Y (TTM)-89.49%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%N/A
Revenue Next Year179.1%
Revenue Next 2Y32.15%
Revenue Next 3Y125.77%
Revenue Next 5Y341.15%
EBIT growth 1Y34.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-38.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.59%
OCF growth 3YN/A
OCF growth 5YN/A

KAZIA THERAPEUTICS-SPON ADR / KZIA Fundamental Analysis FAQ

What is the fundamental rating for KZIA stock?

ChartMill assigns a fundamental rating of 2 / 10 to KZIA.


Can you provide the valuation status for KAZIA THERAPEUTICS-SPON ADR?

ChartMill assigns a valuation rating of 1 / 10 to KAZIA THERAPEUTICS-SPON ADR (KZIA). This can be considered as Overvalued.


What is the profitability of KZIA stock?

KAZIA THERAPEUTICS-SPON ADR (KZIA) has a profitability rating of 1 / 10.


What is the expected EPS growth for KAZIA THERAPEUTICS-SPON ADR (KZIA) stock?

The Earnings per Share (EPS) of KAZIA THERAPEUTICS-SPON ADR (KZIA) is expected to grow by 79.58% in the next year.